# Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE)

> **NCT04733040** · PHASE2 · COMPLETED · sponsor: **HI-Bio, A Biogen Company** · enrollment: 24 (actual)

## Conditions studied

- Glomerulonephritis
- Membranous Nephropathy
- antiPLA2R Positive

## Interventions

- **DRUG:** MOR202

## Key facts

- **NCT ID:** NCT04733040
- **Lead sponsor:** HI-Bio, A Biogen Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-20
- **Primary completion:** 2023-12-14
- **Final completion:** 2023-12-14
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04733040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04733040, "Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04733040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*